Minerva Neurosciences (NERV) EBITDA (2013 - 2026)
Minerva Neurosciences posted quarterly EBITDA of -$16.7 million for Q1 2026, down 327.16% year-on-year from $7.3 million in Q1 2025, and down 234.66% on a QoQ basis from -$5.0 million in Q4 2025.
Minerva Neurosciences (NERV) has 14 years of EBITDA data on file, last reported at -$16.7 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA fell 327.16% year-over-year to -$16.7 million; the trailing twelve-month figure through Mar 2026 stood at -$27.9 million (down 46.16% YoY), and the FY2025 full-year result was -$15.1 million, up 30.87% from the prior year.
- EBITDA for Q1 2026 stood at -$16.7 million, down from -$5.0 million in the prior quarter.
- Across five years, EBITDA topped out at -$2.8 million in Q3 2025 and bottomed at -$16.7 million in Q1 2026.
- The 5-year median for EBITDA is -$5.2 million (2022), against an average of -$6.0 million.
- The widest annual swing landed in 2022, when EBITDA jumped 76.28%; it then slumped 327.16% in 2026.
- A 5-year view of EBITDA shows it stood at -$5.1 million in 2022, then plunged by 41.47% to -$7.2 million in 2023, then jumped by 36.95% to -$4.5 million in 2024, then declined by 10.16% to -$5.0 million in 2025, then plunged by 234.66% to -$16.7 million in 2026.
- The last three EBITDA figures came in at -$16.7 million (Q1 2026), -$5.0 million (Q4 2025), and -$2.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | -16.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.67 Mn |
| Dec 31, 2025 | -4.98 Mn |
| Sep 30, 2025 | -2.84 Mn |
| Jun 30, 2025 | -3.37 Mn |
| Mar 31, 2025 | -3.90 Mn |
| Dec 31, 2024 | -4.52 Mn |
| Sep 30, 2024 | -4.37 Mn |
| Jun 30, 2024 | -6.28 Mn |
| Mar 31, 2024 | -6.68 Mn |
| Dec 31, 2023 | -7.17 Mn |
| Sep 30, 2023 | -6.08 Mn |
| Jun 30, 2023 | -4.52 Mn |
| Mar 31, 2023 | -5.35 Mn |
| Dec 31, 2022 | -5.07 Mn |
| Sep 30, 2022 | -5.21 Mn |
| Jun 30, 2022 | -6.97 Mn |
| Mar 31, 2022 | -7.99 Mn |
| Dec 31, 2021 | -21.38 Mn |
| Sep 30, 2021 | -7.52 Mn |
| Jun 30, 2021 | -8.96 Mn |
| Mar 31, 2021 | -7.51 Mn |
| Dec 31, 2020 | -7.30 Mn |
| Sep 30, 2020 | -8.09 Mn |
| Jun 30, 2020 | 29.51 Mn |
| Mar 31, 2020 | -12.27 Mn |
| Dec 31, 2019 | -32.37 Mn |
| Sep 30, 2019 | -14.28 Mn |
| Jun 30, 2019 | -12.90 Mn |
| Mar 31, 2019 | -16.31 Mn |
| Dec 31, 2018 | -13.63 Mn |
| Sep 30, 2018 | -12.42 Mn |
| Jun 30, 2018 | -12.94 Mn |
| Mar 31, 2018 | -12.74 Mn |
| Dec 31, 2017 | -9.53 Mn |
| Sep 30, 2017 | -11.41 Mn |
| Jun 30, 2017 | -9.75 Mn |
| Mar 31, 2017 | -10.49 Mn |
| Dec 31, 2016 | -9.24 Mn |
| Sep 30, 2016 | -8.23 Mn |
| Jun 30, 2016 | -4.97 Mn |
| Mar 31, 2016 | -7.76 Mn |
| Dec 31, 2015 | -8.19 Mn |
| Sep 30, 2015 | -5.71 Mn |
| Jun 30, 2015 | -6.33 Mn |
| Mar 31, 2015 | -5.88 Mn |
| Dec 31, 2014 | -7.45 Mn |
| Sep 30, 2014 | -27.15 Mn |
| Jun 30, 2014 | -17.65 Mn |
| Mar 31, 2014 | -2.62 Mn |
| Dec 31, 2013 | -2.04 Mn |
| Sep 30, 2013 | -482,000.00 |
| Jun 30, 2013 | -379,000.00 |